United States Patent 9,809,559: What the Claims Actually Cover and How to Map the Landscape
US Patent 9,809,559 is a treatment-method patent that is narrowed to administering a single drug substance defined by three specific salt/hydrate/crystal forms. The enforceable claim scope is therefore not “myelofibrosis or polycythemia vera broadly” but “myelofibrosis/polycythemia vera by dosing one of three named crystalline forms” plus additional characterization limitations that can tighten infringement analysis depending on how the compound is produced and verified.
What is claimed in US 9,809,559 (and what is not)?
Core independent claim
Claim 1 is the only independent claim and sets the fundamental scope:
A method of treating myelofibrosis or polycythemia vera comprising administering to a subject in need thereof a compound selected from:
1) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide dihydrochloride monohydrate, Form II
2) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous, Form I
3) N-(cyanomethyl)-4-(2-(4-morpholinophenylamino)pyrimidin-4-yl)benzamide monohydrochloride anhydrous, Form III
So the patent is a method-of-use claim tethered to specific solid-state forms of the same chemical entity.
Dependent claims add solid-state verification
Claims 2 to 16 progressively narrow the crystalline form and then tie each form to analytical identifiers:
- Claim 2: compound is in a crystalline form.
- Claims 3-8: for Form II, adds:
- Claim 4: unit cell parameters at T = 100 K, with triclinic P-1 space group, and explicit lattice constants/angles:
- a = 10.2837(6) Å
- b = 10.4981(6) Å
- c = 11.5143(7) Å
- α = 83.297(2)°
- β = 87.649(2)°
- γ = 67.445(2)°
- space group: P-1
- Claim 5: XRPD pattern substantially as set forth in FIG. 5
- Claim 6: XRPD peaks at about 7.7°, 19.3°, 24.0°, 25.7°, 29.6° (2-θ ± 0.2°)
- Claim 7: DSC pattern substantially as in FIG. 8
- Claim 8: DVS pattern substantially as in FIG. 14
- Claims 9-12: for Form I, adds:
- Claim 10: XRPD pattern substantially as set forth in FIG. 6
- Claim 11: XRPD peaks at about 13.5°, 20.9°, 26.1°, 26.6°, 28.3° (2-θ ± 0.2°)
- Claim 12: DSC pattern substantially as in FIG. 9
- Claims 13-16: for Form III, adds:
- Claim 14: XRPD pattern substantially as set forth in FIG. 7
- Claim 15: XRPD peaks at about 12.7°, 14.6°, 17.8°, 19.7°, 23.3° (2-θ ± 0.2°)
- Claim 16: DSC pattern substantially as in FIG. 10
What is not covered (scope boundaries)
Based strictly on the provided claim set:
- The patent does not claim free base or other salts beyond these three named forms.
- The independent claim does not expressly require XRPD/DSC/DVS; it requires selecting one of the three forms. But for dependent claims, the solid-state characterization becomes part of the claim’s additional limitations.
- The patent does not claim other indications beyond myelofibrosis and polycythemia vera.
- The patent does not provide dose regimens, routes, or patient selection criteria in the text you provided. Those details, if present, are not in the supplied claims excerpt.
How broad is the claim scope in practice? (form-based infringement risk model)
The practical enforceable “reach” depends on whether the accused product can be shown to contain one of the three claimed crystalline forms.
A. Claim 1 (broadest)
Claim 1 ties infringement to “administering” a patient the compound selected from the three specific solid-state forms. If an accused product contains an equivalent solid form but is not the same as the named Form I/II/III, claim 1 scope narrows sharply.
B. Dependent claims (tightest)
Dependent claims increase evidentiary and technical load by embedding analytical definitions:
- Form II has the most detailed crystallographic support, including:
- unit cell dimensions at 100 K,
- space group P-1,
- plus XRPD, DSC, and DVS patterns.
- Form I and Form III are anchored mainly to:
- XRPD peaks,
- DSC patterns (Form I: FIG. 9; Form III: FIG. 10),
- and the relevant “substantially as” figure-based patterns.
In litigation or challenge, this generally shifts the fact pattern toward a solid-state identity fight: did the product delivered to patients correspond to those forms as defined by crystallographic/thermal/sorption behavior?
What are the “fingerprints” each form has to match?
Form II (dihydrochloride monohydrate)
- Unit cell at 100 K (triclinic P-1):
- a 10.2837(6) Å
- b 10.4981(6) Å
- c 11.5143(7) Å
- α 83.297(2)°
- β 87.649(2)°
- γ 67.445(2)°
- XRPD peak set (Claim 6):
- ~7.7°, 19.3°, 24.0°, 25.7°, 29.6° (2-θ ± 0.2°)
- Additional analytical dependencies:
- XRPD “substantially as” FIG. 5 (Claim 5)
- DSC “substantially as” FIG. 8 (Claim 7)
- DVS “substantially as” FIG. 14 (Claim 8)
Implication: Form II is the most constrained; solid-state comparisons typically need both powder diffraction and at least one other orthogonal method (thermal and/or vapor sorption) to convincingly map identity.
Form I (monohydrochloride anhydrous)
- XRPD peak set (Claim 11):
- ~13.5°, 20.9°, 26.1°, 26.6°, 28.3° (2-θ ± 0.2°)
- Additional dependencies:
- XRPD “substantially as” FIG. 6 (Claim 10)
- DSC “substantially as” FIG. 9 (Claim 12)
Implication: Form I identity analysis can focus on the specified XRPD peak positions and thermal profile, but the “substantially as” language still invites peak-shape and relative-intensity argument.
Form III (monohydrochloride anhydrous)
- XRPD peak set (Claim 15):
- ~12.7°, 14.6°, 17.8°, 19.7°, 23.3° (2-θ ± 0.2°)
- Additional dependencies:
- XRPD “substantially as” FIG. 7 (Claim 14)
- DSC “substantially as” FIG. 10 (Claim 16)
Implication: Form III also is crystallinity-anchored by XRPD and DSC, enabling a targeted form-discrimination strategy.
Claim-by-claim landscape summary (what each claim adds in enforcement value)
| Claim |
Treatment scope |
Solid-state requirement |
Analytical hook(s) |
| 1 |
Treat myelofibrosis or polycythemia vera |
Administer Form II / Form I / Form III as listed |
None beyond the form identity selection |
| 2 |
Same as claim 1 |
Crystalline form |
Crystallinity baseline |
| 3 |
Same as claim 1 |
Requires Form II |
Locks to dihydrochloride monohydrate |
| 4 |
Same as claim 1 |
Requires Form II |
Unit cell at 100 K + P-1 |
| 5 |
Same as claim 3 |
Requires Form II |
XRPD “substantially as FIG. 5” |
| 6 |
Same as claim 3 |
Requires Form II |
XRPD peaks: 7.7°, 19.3°, 24.0°, 25.7°, 29.6° ±0.2° |
| 7 |
Same as claim 3 |
Requires Form II |
DSC “substantially as FIG. 8” |
| 8 |
Same as claim 3 |
Requires Form II |
DVS “substantially as FIG. 14” |
| 9 |
Same as claim 2 |
Requires Form I |
Crystalline Form I monohydrochloride anhydrous |
| 10 |
Same as claim 9 |
Requires Form I |
XRPD “substantially as FIG. 6” |
| 11 |
Same as claim 9 |
Requires Form I |
XRPD peaks: 13.5°, 20.9°, 26.1°, 26.6°, 28.3° ±0.2° |
| 12 |
Same as claim 9 |
Requires Form I |
DSC “substantially as FIG. 9” |
| 13 |
Same as claim 2 |
Requires Form III |
Crystalline Form III monohydrochloride anhydrous |
| 14 |
Same as claim 13 |
Requires Form III |
XRPD “substantially as FIG. 7” |
| 15 |
Same as claim 13 |
Requires Form III |
XRPD peaks: 12.7°, 14.6°, 17.8°, 19.7°, 23.3° ±0.2° |
| 16 |
Same as claim 13 |
Requires Form III |
DSC “substantially as FIG. 10” |
Patent landscape mapping: what you can infer from the claim structure alone
With only the claims provided, the landscape signals are limited to what the patent is doing legally: it is protecting crystalline form-specific method-of-use rather than general efficacy or broad chemical structure claims.
1) Likely competitive attack surfaces
A challenger’s most direct technical strategy, given the dependent claim hooks, is to contest whether an accused solid form is truly the same as Form I/II/III:
- Different hydrate/anhydrate relationship (Form II includes a monohydrate; Forms I/III are anhydrous).
- Different polymorph identity between Form I and Form III (both are monohydrochloride anhydrous but distinct).
- Different XRPD peak matching outside the “substantially as” tolerance argument.
- Different DSC signatures, and for Form II, DVS behavior.
2) Likely commercial and R&D positioning
For development teams, this kind of patent architecture typically forces decisions around:
- Solid-state control strategy (how you choose and lock a polymorph)
- Solid form analytics for batch release (XRPD and DSC, and for Form II, potentially DVS)
- Comparative analytical studies against the cited figure/pattern definitions
3) Litigation evidence tends to be analytical
Because multiple dependent claims recite XRPD peaks and thermal behaviors, the case record is likely to depend heavily on:
- XRPD pattern and peak-position comparisons at comparable instrument settings
- DSC onset/enthalpy patterns matching “substantially as” references
- For Form II, DVS is an additional discriminator
Key Takeaways
- US 9,809,559 is a form-tethered method-of-use patent: it covers treating myelofibrosis or polycythemia vera by administering one of three named crystalline salt/hydrate forms of the same compound.
- Claim 1 is broad within the three named forms; dependent claims for Form II, Form I, and Form III add crystal identity proof points (XRPD/DSC, and for Form II also DVS plus unit cell parameters at 100 K and P-1).
- The practical infringement question is solid-state identity: whether the administered material corresponds to Form II, Form I, or Form III as defined by the claim-linked analytical patterns and crystallographic parameters.
- The competitive and legal risk concentrates on polymorph/hydrate transitions and analytical distinguishability between Forms I and III and between anhydrous vs hydrated Form II.
FAQs
1) Does US 9,809,559 cover any compound for myelofibrosis/polycythemia vera?
No. It covers administration of the specific compound in one of the three listed solid forms (Form II, Form I, Form III).
2) Which form has the tightest structural definition in the claim set?
Form II. It includes explicit unit cell parameters at 100 K and triclinic P-1, plus XRPD, DSC, and DVS references.
3) Are XRPD and DSC required in every claim?
No. XRPD/DSC are required through dependent claims (not the independent Claim 1). Claim 1 depends on selecting among the defined forms.
4) Are Form I and Form III both monohydrochloride anhydrous?
Yes. Both are described as monohydrochloride anhydrous but are distinct crystalline forms with different XRPD peak sets and figure-based patterns.
5) What is the fastest technical way to assess freedom-to-operate for this patent family using only the claim language?
Compare the candidate drug substance to the claim-linked solid-state identifiers for each form: XRPD peak positions (and DSC, plus DVS for Form II) and, for Form II, the unit cell and space group constraints.
References
[1] United States Patent US 9,809,559. Claims 1-16 (method of treating myelofibrosis or polycythemia vera with specified crystalline forms; XRPD/DSC/DVS and unit cell parameters).
